<DOC>
	<DOCNO>NCT01036399</DOCNO>
	<brief_summary>Revlimid potent immunomodulatory analogue without teratogenic effect , direct anti-tumor effect , anti-angiogenic anti-inflammatory T-cell costimulatory property . Both preclinical clinical data indicate efficacy solid tumor multiple myeloma include advanced/refractory stage role enhance host antitumor immunity provide rationale use patient PTCL .</brief_summary>
	<brief_title>Study Lenalidomide ( Revlimid ) Patients With Relapsed/Refractory Peripheral T-cell Lymphoma ( PTCL ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients histologic diagnosis PTCL accord WHOREAL classification ; Age &gt; 18 year ; Relapsed ( Â³1 ) refractory conventional chemotherapy/radiotherapy ; Stage IIV accord Ann Arbor stag System ; Performance status &lt; 2 ; Adequate bone marrow reserve : platelet &gt; 50 x 10 ( 9 ) /L , absolute neutrophil count ( ANC ) &gt; 1.0 x 10 ( 9 ) /L , hemoglobin &gt; 8 g/d ; Normal renal hepatic function ; Negative HIV , HCV , HBV status ; Informed consent prior registration study Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 28 day baseline . Known hypersensitivity thalidomide . The development erythema characterize desquamate rash take thalidomide similar drug . Any prior use lenalidomide . Concurrent use anticancer agent treatment . Known positive HIV infectious hepatitis , type A , B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>PTCL</keyword>
</DOC>